Cadaveric liver transplantation for non-acetaminophen fulminant hepatic failure: A 20-year experience

Olivier Detry, Arnaud De Roover, Carla Coimbra, Jean Delwaide, Marie-France Hans, Marie Hélène Delbouille, José Monard, Jean Joris, Pierre Damas, Jacques Belaïche, Michel Meurisse, Pierre Honoré

AIM: To investigate the long-term results of liver transplantation (LT) for non-acetaminophen fulminant hepatic failure (FHF).

METHODS: Over a 20-year period, 29 FHF patients underwent cadaveric whole LT. Most frequent causes of FHF were hepatitis B virus and drug-related (not acetaminophen) liver failure. All surviving patients were regularly controlled at the out-patient clinic and none was lost to follow-up. Mean follow-up was 101 mo.

RESULTS: One month, one-, five- and ten-year patient survival was 79%, 72%, 68% and 68%, respectively. One month, one-, five- and ten-year graft survival was 69%, 65%, 51% and 38%, respectively. Six patients needed early (< 2 mo) retransplantation, four for primary non-function, one for early acute refractory rejection because of ABO blood group incompatibility, and one for a malignant tumor found in the donor. Two patients with hepatitis B FHF developed cerebral lesions peri-transplantation: one developed irreversible and extensive brain damage leading to death, and one suffered from deep deficits leading to continuous medical care in a specialized institution.

CONCLUSION: Long-term outcome of patients transplanted for non-acetaminophen FHF may be excellent. As the quality of life of these patients is also particularly good, LT for FHF is clearly justified, despite lower graft survival compared with LT for other liver diseases.

© 2007 The WJG Press. All rights reserved.

Key words: Liver transplantation; Liver failure; Surgery; Hepatitis B; Liver support

INTRODUCTION

Fulminant hepatic failure (FHF) is a rare but a dreadful disease affecting mostly young patients. FHF is mainly managed based on symptoms, the identification of the FHF causes requiring specific treatment and supportive care, as FHF patients have chances of recovery[1]. The main causes of death of FHF patients are intracranial hypertension leading to brain stem death, and sepsis with multiple organ failure (MOF)[2]. Many liver support systems have been tried, but the ideal and efficient artificial liver has still to be designed and its efficacy to be proven[3]. In the sickest cases, when established predicting factors of death are reached, liver transplantation (LT) has been established as the standard treatment for FHF patients[4]. However, the results of LT for FHF may be disappointing, especially compared with the results of LT for chronic liver diseases since FHF patients often suffer from risk factors for graft failure or high morbidity or/and mortality[5].

In the United States of America (USA) and in the United Kingdom (UK), FHF is very frequently caused by acetaminophen intoxication[6-9]. However this etiology is far less frequent in other Western countries. The aim of this study is to report the 20-year experience and the results of LT for non-acetaminophen FHF of the liver transplantation program of the University of Liège, Belgium, a transplantation center working within the Eurotransplant allocation system. As many variables changed during such a long period of time, the authors
focused this report on the outcome of FHF patients who underwent LT.

MATERIALS AND METHODS

The liver transplantation program of the University of Liège started in 1986[10]. From 1986 to December 2005, 345 cases of LT were performed, mostly in adult patients, including 7 adult-to-adult living-related LT[11]. Among this series, 58 patients were listed for Hyper Urgent (HU) LT, meaning patients with FHF, or patients requiring urgent retransplantation for primary non-function (PNF) or vascular thrombosis after LT. Thirty-two patients were registered for FHF. All these patients were suffering from FHF as defined by the occurrence of encephalopathy within 8 wk after jaundice development in patients without previous histories of liver disease[12]. All reached the established criteria for bad prognosis as established by the Clichy’s group (non-acetaminophen FHF group) or the King’s College (acetaminophen FHF group) [13,14]. Three patients who suffered from acetaminophen FHF and who met the King’s College criteria for bad prognosis, recovered under medical therapy and intravenous N-acetylcysteine therapy. They were removed for subsequent analysis.

All patients were hospitalized in the intensive care unit and underwent standard medical therapy[11]. None but one patient received liver support with the Molecular Adsorbents Recirculating System (MARS). Patients in encephalopathy stage III were intubated for airway protection, if necessary. Continuous veno-venous hemofiltration was used for renal support. No patient underwent intracranial pressure monitoring.

All patients were registered for HU cadaveric LT in the Eurotransplant allocation system. Until 1992, transplantation of an ABO non-compatible liver graft was authorized for recipient life-saving purpose. As results of the non-compatible LT were not satisfactory in terms of graft survival, ABO compatible LT was required after 1992. All patients were transplanted with cadaveric whole liver. Orthotopic whole LT with veno-venous bypass was performed as the standard LT procedure from 1986 to 1994. After 1995 the standard surgical procedure for LT was the Belghiti’s technique, i.e. a piggy-back LT with temporary surgical porto-caval shunt, without use of veno-venous bypass and with large cavo-caval side-to-side anastomosis as venous reconstruction[15,16]. During this 20-year period, many other variables changed in the management of patients with FHF and of LT recipients. Immunosuppressive protocols in triple therapy regimens included cyclosporine/tacrolimus, Imuran/Cellcept and steroids. Steroids were progressively weaned, and most patients were under calcineurin inhibitor monotherapy at one-year follow-up. Patients transplanted for hepatitis B virus (HBV) FHF received life-long immunoprophylaxis with intravenous anti-HBs antibodies (10000 UI every 3-4 mo, aiming at a minimum blood level > 100 mUI/mL).

All surviving patients were regularly controlled at the out-patient clinic and none was lost to follow-up. Mean follow-up was 101 mo (range: 5–204 mo). Statistical analysis was undertaken using patient and graft survival as endpoints. Survival was calculated using the method of Kaplan-Meier.

RESULTS

Twenty-nine patients (nine males, twenty females; mean age 39 years, range: 14–66 years) who developed non-acetaminophen FHF, were listed for cadaveric LT and underwent transplantation. The etiology of FHF is presented in Table 1. Most frequent causes of FHF in this group were hepatitis B virus (HBV) and drug-related. Three patients were in encephalopathy stage III, 10 in stage III and 16 in stage IV, at time of LT listing. Mean factor V level was 16% (range: 5%-31%). Mean waiting time between listing for HU LT and availability of a liver graft was 23 h (range: 4–49 h). Twenty patients were mechanically ventilated at time of listing and until LT. Nineteen developed acute renal failure and needed hemofiltration. Mean cadaveric donor age was 40 years (range: 14–57 years). Mean total graft ischemia was 417 min (range: 245-750 min). One month, one-, five- and ten-year survival was 79%, 72%, 68% and 68%, respectively (Figure 1). All patients who survived the first two years were alive at follow-up. Causes of early death (< 2 mo) were MOF, PNF (1 case) and peri-operative brain death (1 case). The only patient who died after 2 mo was not compliant to medical therapy after transplantation, suffered from chronic allograft rejection but was denied

Table 1  Causes of fulminant hepatic failure in this series

<table>
<thead>
<tr>
<th>Causes</th>
<th>No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Viral infection</td>
<td>12</td>
</tr>
<tr>
<td>Drug induced</td>
<td>5</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>7</td>
</tr>
<tr>
<td>Budd-Chiari</td>
<td>1</td>
</tr>
<tr>
<td>Wilson</td>
<td>2</td>
</tr>
<tr>
<td>Ischemic</td>
<td>2</td>
</tr>
<tr>
<td>Alcohol</td>
<td>1</td>
</tr>
<tr>
<td>Autoimmune</td>
<td>1</td>
</tr>
<tr>
<td>Undetermined</td>
<td>5</td>
</tr>
</tbody>
</table>

HBV: hepatitis B virus; HAV: hepatitis A virus.

Figure 1  Patient and graft survivals after liver transplantation for fulminant hepatic failure according to the Kaplan-Meier method.

Kaplan-Meier.
for re-transplantation (died at 18 mo of follow-up).

Six patients needed early (< 2 mo) re-LT, 4 for PNF, 1 for early acute refractory rejection because of ABO blood group incompatibility, and 1 for a malignant tumor found in the donor[17]. Three patients needed late (> 2 mo) re-transplantation due to chronic rejection or chronic graft dysfunction due to ABO blood group incompatibility in two cases and to non-compliance in one case. One patient needed a third transplantation because of chronic cholangitis on the second graft. One month, one-, five- and ten-year graft survival was 69%, 65%, 51% and 38%, respectively (Figure 1).

In the group of long-term survivors, two young females later enjoyed a total of three normal pregnancies. Among the patients transplanted for HBV FHF, one developed HBV graft re-infection treated first by lamivudine, and afterwards adefovir when the virus became resistant to lamivudine. This patient is well at follow-up, with graft biopsy of recipient age and history of life support have been established as significant risk factors for post-LT death in FHF patients[12,18].

In conclusion, this series confirmed that long-term outcome of patients transplanted for non-acetaminophen FHF may be excellent. As the quality of life of these patients is also particularly good, these results proved that LT for FHF is clearly justified, despite lower graft survival compared to LT for other liver diseases.

REFERENCES

6 Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan


